Previous Close | 24.55 |
Open | 24.80 |
Bid | 24.46 x N/A |
Ask | 24.51 x N/A |
Day's Range | 24.23 - 24.85 |
52 Week Range | 23.40 - 47.60 |
Volume | |
Avg. Volume | 1,207,283 |
Market Cap | 13.72B |
Beta (5Y Monthly) | 1.13 |
PE Ratio (TTM) | 7.64 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | 0.92 (3.75%) |
Ex-Dividend Date | May 16, 2022 |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for FRE.DE
(Reuters) -Shares in the world's largest kidney dialysis provider Fresenius Medical Care (FMC) plunged more than 12% to a 12-year low on Thursday after it cut its earnings outlook as costs surge and a U.S. staff shortage leaves it scrambling for nurses. In an unscheduled statement late on Wednesday, FMC flagged a decline in net income approaching 20% this year and withdrew its 2025 targets. Most of its U.S. patients are covered by state-run insurer Medicare, with lump-sum reimbursements per patient that only get adjusted to cost inflation with a two-year delay, the chief executive of FMC parent Fresenius, Stephan Sturm, said on an analyst call.
The heavy selling pressure might have exhausted for Fresenius (FMS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.